Analyst Activity – Morgan Stanley Initiates Coverage On Cytokinetics, Incorporated (NASDAQ:CYTK) With a Overweight

ME Staff
-
0

Analyst Ratings For Cytokinetics, Incorporated (NASDAQ:CYTK)

Today, Morgan Stanley initiated coverage on Cytokinetics, Incorporated (NASDAQ:CYTK) with a Overweight with a price target of $24.00.

There are 9 buy ratings, 1 strong buy rating on the stock.

The current consensus rating on Cytokinetics, Incorporated (NASDAQ:CYTK) is Buy (Score: 3.10) with a consensus target price of $21.40 per share, a potential 49.85% upside.

Some recent analyst ratings include

  • 7/31/2017-Morgan Stanley initiated coverage with a Overweight rating.
  • 5/19/2017-Cantor Fitzgerald Reiterated Rating of Overweight.
  • 4/29/2017-Cowen and Company Reiterated Rating of Outperform.
  • 4/25/2017-HC Wainwright Reiterated Rating of Buy.
  • 3/23/2017-Rodman & Renshaw Reiterated Rating of Buy.
  • 2/17/2017-FBR & Co Reiterated Rating of Outperform.
  • 2/17/2017-Needham & Company LLC Reiterated Rating of Strong-Buy.

Recent Insider Trading Activity For Cytokinetics, Incorporated (NASDAQ:CYTK)
Cytokinetics, Incorporated (NASDAQ:CYTK) has insider ownership of 7.20% and institutional ownership of 59.65%.

  • On 7/3/2017 Robert I Blum, CEO, sold 5,000 with an average share price of $12.14 per share and the total transaction amounting to $60,700.00. View SEC Filing
  • On 6/1/2017 Robert I Blum, CEO, sold 5,000 with an average share price of $13.62 per share and the total transaction amounting to $68,100.00. View SEC Filing
  • On 12/29/2016 Fady Ibraham Malik, EVP, sold 5,633 with an average share price of $12.36 per share and the total transaction amounting to $69,623.88. View SEC Filing
  • On 8/31/2015 L Patrick Gage, Director, bought 1,000 with an average share price of $6.95 per share and the total transaction amounting to $6,950.00. View SEC Filing
  • On 8/20/2015 L Patrick Gage, Director, bought 10,000 with an average share price of $6.55 per share and the total transaction amounting to $65,500.00. View SEC Filing
  • On 5/6/2015 L Patrick Gage, Director, bought 10,000 with an average share price of $5.71 per share and the total transaction amounting to $57,100.00. View SEC Filing
  • On 3/11/2015 Andrew A Wolff, CMO, sold 21,875 with an average share price of $7.80 per share and the total transaction amounting to $170,625.00. View SEC Filing

Recent Trading Activity for Cytokinetics, Incorporated (NASDAQ:CYTK)
Shares of Cytokinetics, Incorporated closed the previous trading session at 14.12 down -0.07 -0.53% with 188,988 shares trading hands.